1. Introduction {#sec1-marinedrugs-14-00017}
===============

1.1. Marine Natural Products {#sec1dot1-marinedrugs-14-00017}
----------------------------

Dating back to ancient civilizations, natural products have played a vital role in drug discovery. Modern day drugs such as penicillin, morphine, and paclitaxel (Taxol™), which are used for the treatment of bacterial infections, pain, and cancer, respectively, are examples of natural products that have successfully progressed through the drug development pipeline. Natural products are abundant in several sources and are routinely extracted from plants, microorganisms, and animals. While terrestrial plants and terrestrial microbes continue to be the primary contributors to the natural product derived drug market, marine sources are an emerging resource that has been relatively unexplored until recent times \[[@B1-marinedrugs-14-00017]\]. Marine organisms are considered to yield superior natural products compared to terrestrial organisms in terms of novelty of structures and in producing potent bioactivities, due to the distinctive environmental conditions in which marine organisms live \[[@B2-marinedrugs-14-00017],[@B3-marinedrugs-14-00017],[@B4-marinedrugs-14-00017]\]. Factors such as predation, competition for space on highly populated coral reefs, and biochemical warfare between organisms have greatly contributed to the evolution of compounds with unique structures and potent biological effects \[[@B5-marinedrugs-14-00017]\].

1.2. Cyanobacteria {#sec1dot2-marinedrugs-14-00017}
------------------

Microbial organisms in the marine environment have increasingly become one of the major focal points for investigations seeking to identify new chemical entities with novel structural backbones and diverse biological activities. In the 1970s, Professor Richard E. Moore at the University of Hawaii began exploring the chemistry of marine cyanobacteria \[[@B6-marinedrugs-14-00017]\]. Cyanobacteria are one of the oldest organisms on Earth, with an existence record of at least 2.7 billion years \[[@B7-marinedrugs-14-00017]\]. These prokaryote organisms are also known as blue green algae, cyanoprokaryotes, and cyanophytes due to their blue-green pigment, c-PC (c-phycocyanin) \[[@B8-marinedrugs-14-00017]\]. This pigment is used for photosynthesis and is considered to have played a crucial role in releasing oxygen into the primitive atmosphere \[[@B7-marinedrugs-14-00017],[@B9-marinedrugs-14-00017]\]. Cyanobacteria possess a broad geographical distribution, ranging from limnic and marine environments to terrestrial habitats \[[@B10-marinedrugs-14-00017],[@B11-marinedrugs-14-00017]\].

A subclass of marine natural compounds is produced by cyanobacteria. The most studied species of marine cyanobacteria include *Nostoc*, *Calothrix*, *Lyngbya*, and *Symploca* \[[@B12-marinedrugs-14-00017]\]. Cyanobacteria are known to produce potent toxins. Several studies have investigated the pharmaceutical and biotechnological potential of the secondary metabolites isolated from cyanobacteria. These studies revealed a wide range of potent pharmacological effects that include anti-inflammatory, antimalarial, antiprotozoal, antimicrobial, immunosuppressant, anticancer, anti-HIV, antibacterial, anticoagulant, antifungal, anti-tuberculosis, antiviral, and antitumor activities \[[@B12-marinedrugs-14-00017],[@B13-marinedrugs-14-00017],[@B14-marinedrugs-14-00017]\]. A number of compounds that were isolated from aquatic cyanobacteria have showed promise as anticancer leads. Examples of such promising compounds include apratoxin A, cryptophycin, dolastatin 10, and largazole ([Figure 1](#marinedrugs-14-00017-f001){ref-type="fig"}).

![Biologically active natural products isolated from marine cyanobacteria.](marinedrugs-14-00017-g001){#marinedrugs-14-00017-f001}

Apratoxin A is a cyclodepsipeptide derivative of the apratoxin family of cytotoxins isolated from a *Lyngbya* sp. collected from Guam \[[@B15-marinedrugs-14-00017],[@B16-marinedrugs-14-00017]\]. It induces G~1~ phase cell cycle arrest and apoptosis, and has exhibited IC~50~ values ranging from 0.36 to 0.52 nM *in vitro* against 60 human tumor cell lines. However, *in vivo* studies revealed only marginal activity against early stage adenocarcinoma \[[@B17-marinedrugs-14-00017],[@B18-marinedrugs-14-00017],[@B19-marinedrugs-14-00017]\]. Another class of highly potent anticancer agents produced by cyanobacteria is cryptophycins. For example, cryptophycin 1, which was isolated from *Nostoc* sp. GSV224, has an IC~50~ of 5 pg/mL against KB human nasopharyngeal cancer cells, and 3 pg/mL against LoVo human colorectal cancer cells \[[@B20-marinedrugs-14-00017]\]. Its mechanism of action is through the suppression of microtubule dynamics, thereby inhibiting cells in G~2~/M phase. Cryptophycin 52, a chemical analog of cryptophycin 1, entered clinical trials but produced only marginal activity \[[@B21-marinedrugs-14-00017]\].

Dolastatin 10 is cyanobacterial metabolite that was synthesized by Pettit *et al.* \[[@B22-marinedrugs-14-00017],[@B23-marinedrugs-14-00017]\] in the 1980s and then its origin was later confirmed when its direct isolation occurred from *Symploca* sp. Dolastatin 10 binds to tubulin on the rhizoxin-binding site and is an established antiproliferative agent that affects microtubule assembly, which leads to cell death during the G~2~/M phase \[[@B24-marinedrugs-14-00017]\]. In 2005, the efficacy and toxicity of dolastatin 10 were investigated in Phase II clinical trials in patients with advanced prostate cancer but it was discontinued due to the development of peripheral neuropathy in 40% of the patients \[[@B25-marinedrugs-14-00017]\]. Many research groups have sought after SAR studies of the synthetic analogs of this compound, which are now classified as auristatins. This group of compounds showed the most amount of promise as antibody drug conjugates. For example, brentuximab vedotin (adcetris, Seattle Genetics ) is now a FDA-approved drug against lymphoma. This compound is currently undergoing phase 3 studies to study its effect on cutaneous T-cell lymphoma, B-cell lymphomas, and mature T-cell lymphomas \[[@B26-marinedrugs-14-00017],[@B27-marinedrugs-14-00017]\].

The cyclic depsipeptide largazole, of the genus *Symploca*, is a marine natural product that contains a methylthiazoline linked to a thiazole, as well as a 3-hydroxy-7-mercaptohept-4-enoic acid unit, and a thioester, which had previously not been observed in marine cyanobacterial natural products. This compound has been shown to selectively target transformed over non-transformed cells \[[@B28-marinedrugs-14-00017],[@B29-marinedrugs-14-00017]\], through the inhibition of class I histone deacetylases (HDACs) \[[@B30-marinedrugs-14-00017],[@B31-marinedrugs-14-00017]\]. Largazole's interesting structure and biological activity have attracted strong interest from the synthetic chemistry community, which seeks to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic \[[@B32-marinedrugs-14-00017],[@B33-marinedrugs-14-00017]\].

Thus, cyanobacterial metabolites have the potential for expanded utilization in drug discovery. Despite their potent biological activities, very few cyanobacterial compounds have entered clinical trials; one of the reasons is the complexity of synthesis of the natural products. The focus of this review is the natural products called calothrixins, with an emphasis on their synthesis and bioactivities.

1.3. Calothrixins {#sec1dot3-marinedrugs-14-00017}
-----------------

Calothrixins A and B ([Figure 2](#marinedrugs-14-00017-f002){ref-type="fig"}) are two cyanobacterial metabolites that were first isolated from *Calothrix* in 1999 by Rickards *et al.* \[[@B34-marinedrugs-14-00017]\]. Briefly, lyophilized cells of *Calothrix* strains were extracted with dimethyl sulfoxide (DMSO) and then with ethyl acetate (AcOEt) using Soxhlet extraction conditions. These extracts were fractionalized using a combination of bioassays, differential solubility, and chromatography, which yielded the relatively insoluble calothrixin A (1a) and its more soluble co-metabolite, calothrixin B (1b). Both structures were elucidated by Electron Impact Mass Spectra (EIMS), ^1^H, ^13^C and ^1^H--^1^H Correlation Spectroscopy (COSY) NMRs. Calothrixins possess an unique indolo\[3,2-*j*\]phenanthridine framework with an assembly of quinoline, quinone, and indole pharmacophores. Calothrixin B is generally known to be the neutral analog while calothrixin A is known to be its *N*-oxide analog.

![Structures of calothrixins.](marinedrugs-14-00017-g002){#marinedrugs-14-00017-f002}

These scaffolds have attracted the interests of organic chemists and biologists alike due to their unique structures and the promise they hold as lead compounds for cancer drug discovery. Herein, we summarize the recent advances in synthetic work on calothrixins and their analogs.

2. Synthesis of Calothrixins {#sec2-marinedrugs-14-00017}
============================

Due to the structural complexity and drug discovery potential, organic and medicinal chemists around the world have embarked on developing efficient synthetic methodologies to produce these natural products. Earlier synthesis of calothrixins was reviewed in 2009 by Satoshi Hibino *et al.* \[[@B35-marinedrugs-14-00017]\]. There has been a lot of progress made in the synthesis of calothrixins and their analogs since then. Herein, the discussion will focus on the progress achieved within the past six years in developing new synthetic routes to achieve the large-scale production of calothrixins.

The calothrixin scaffold consists of five rings (A--E), as shown in [Figure 2](#marinedrugs-14-00017-f002){ref-type="fig"}. Multiple synthetic strategies have been used to synthesize calothrixins starting from suitably substituted indole, quinoline, or carbazole derivatives. The synthetic routes for calothrixins are categorized into three main groups based on the strategy of the last ring closure step in the construction of the calothrixin scaffold (1) ring B closure; (2) ring C closure; and (3) ring D closure ([Table 1](#marinedrugs-14-00017-t001){ref-type="table"}). No syntheses have been reported in which either ring A or ring E are constructed as the last ring closure step. Recent reports on the synthesis of calothrixins and the key reactions involved in these syntheses are summarized in [Table 1](#marinedrugs-14-00017-t001){ref-type="table"}.

marinedrugs-14-00017-t001_Table 1

###### 

Summary of reported syntheses of calothrixin B since 2009.

  Research Group            Year          Ring Closure   Key Step                                                                    Reference
  ------------------------- ------------- -------------- --------------------------------------------------------------------------- -------------------------------------------------------------
  Velu *et al.*             2014          B              Mn(OAc)~3~ mediated oxidative free radical reaction                         \[[@B36-marinedrugs-14-00017]\]
  Ishikura *et al.*         2011 & 2012   C              Palladium catalyzed tandem cyclization/cross-coupling                       \[[@B37-marinedrugs-14-00017],[@B38-marinedrugs-14-00017]\]
  Dethe *et al.*            2014          C              LTA mediated rearrangement of *o*-hydroxy aryl hydrazone                    \[[@B39-marinedrugs-14-00017]\]
  Nagarajan *et al.*        2014          C              Friedel-Crafts hydroxyalkylation and directed *o*-lithiation                \[[@B40-marinedrugs-14-00017]\]
  Mal *et al.*              2014          C              The anionic annulation of MOM-protected furoindolone                        \[[@B41-marinedrugs-14-00017]\]
  Kusurkar *et al.*         2012          D              Two one pot reaction sequences: a nucleophilic substitution and reduction   \[[@B42-marinedrugs-14-00017]\]
  Nagarajan *et al.*        2013          D              Pd catalyzed intramolecular cross-coupling reaction via C--H activation     \[[@B43-marinedrugs-14-00017]\]
  Mohanakrishnan *et al.*   2014          D              Electrocyclization of 2-nitroarylvinyl-3-phenylsulfonylvinylindole          \[[@B44-marinedrugs-14-00017]\]
  Kumar *et al.*            2014          D              Pd mediated intramolecular C-X/C-H cross coupling reactions                 \[[@B45-marinedrugs-14-00017]\]
  Hibino *et al.*           2012          D              Allene mediated electrocyclic reaction of the 6π-electron system            \[[@B46-marinedrugs-14-00017]\]
  Mohanakrishnan *et al.*   2013          C & D          FeCl~3~ mediated domino reaction of enamines                                \[[@B47-marinedrugs-14-00017]\]

2.1. Formation of Indole (Rings A and B) as the Last Step in the Construction of the Indolo\[3,2-j\]Phenanthridine Framework {#sec2dot1-marinedrugs-14-00017}
----------------------------------------------------------------------------------------------------------------------------

### Velu's Synthesis

In 2014, Velu *et al.* \[[@B36-marinedrugs-14-00017]\] reported a synthesis of calothrixins in which the indole ring is formed last to construct the five-ring scaffold. This approach relies on the construction of the indole ring (rings A and B) on a phenanthridine dione (ring C, D, and E) via a novel oxidative free radical reaction mediated by manganese triacetate Mn(OAc)~3~, as outlined in [Scheme 1](#marinedrugs-14-00017-f003){ref-type="scheme"}. The method of Mn(OAc)~3~ mediated oxidative reaction of 2-cyclohexenone with quinones was originally developed by Chuang *et al.* \[[@B48-marinedrugs-14-00017],[@B49-marinedrugs-14-00017],[@B50-marinedrugs-14-00017]\]. None of the existing reports of calothrixin synthesis utilizes the late-stage indole construction strategy. Through this methodology, calothrixin B was synthesized in seven steps, with an overall yield of 19% starting from 2,4,5-trimethoxyindole.

![Velu's synthesis of calothrixins.](marinedrugs-14-00017-g003){#marinedrugs-14-00017-f003}

2.2. Ring C Closure as the Last Step in the Construction of the Indolo\[3,2-j\]Phenanthridine Framework {#sec2dot2-marinedrugs-14-00017}
-------------------------------------------------------------------------------------------------------

A number of calothrixin syntheses have been reported where the ring C closure was used as the last step in the construction of calothrixin scaffold. This includes the two syntheses reported by Ishikura *et al.* in 2011 and 2012 \[[@B37-marinedrugs-14-00017],[@B38-marinedrugs-14-00017]\], and the three contributions made by Dethe *et al.* \[[@B39-marinedrugs-14-00017]\], Nagarajan *et al.* \[[@B40-marinedrugs-14-00017]\], and Mal *et al.* \[[@B41-marinedrugs-14-00017]\] in 2014.

### 2.2.1. Ishikura's Synthesis {#sec2dot2dot1-marinedrugs-14-00017}

Ishikura *et al.* \[[@B37-marinedrugs-14-00017],[@B38-marinedrugs-14-00017]\] was one of the first groups that designed a synthetic route to calothrixins in which ring C was cyclized last as shown in [Scheme 2](#marinedrugs-14-00017-f004){ref-type="scheme"}. In their ongoing studies of trialkyl(indol-2-yl)borates, they previously found that indolylborates show high reactivity in palladium-catalyzed cross-coupling reactions, such as carbonylative cross-coupling and tandem cyclization/cross-coupling reactions. This new approach for the synthesis of calothrixins A and B was demonstrated through a palladium-catalyzed cross-coupling reaction of 1-methoxyindolylborate (generated *in situ* from 1-methoxyindole by treatment with n-BuLi and BEt~3~) with the intermediate compound **13** to form the compound **15**. Additional novelty of this synthetic route is the strategic use of Cu(OTf)~2~.toluene complex for the 6π-elecrocyclization of the hexatriene intermediate (**16**) to cyclize the ring C to form the compound **17**. Ishikura's synthesis yielded calothrixin B in nine steps with an overall yield of 9% starting from 2-iodoaniline.

![Ishikura's synthesis of calothrixins.](marinedrugs-14-00017-g004){#marinedrugs-14-00017-f004}

### 2.2.2. Dethe's Synthesis {#sec2dot2dot2-marinedrugs-14-00017}

Dethe *et al.* \[[@B39-marinedrugs-14-00017]\] reported a concise five-step total synthesis of calothrixin B using LTA-mediated rearrangement of a suitable *o*-hydroxy aryl hydrazone into the corresponding quinone as the key step, as outlined in [Scheme 3](#marinedrugs-14-00017-f005){ref-type="scheme"}. The synthesis began with the coupling of *N*-PMB (p-methoxy benzyl) protected indolyl hyrazide (**21**) and the quinolinone derivative (**22**) to form the intermediate hydrazone **23**. The hydrazone (**23**) was treated with Pb(OAc)~4~ to undergo the LTA-mediated oxidative rearrangement followed by a BF~3~.OEt~2~-mediated cyclization to form the PMB-protected calothrixin B (**25**). This synthesis is short and high yielding. The overall yield of the calothrixin B synthesis from ethyl indole-2-carboxylate (**20**) is 39% for five steps.

![Dethe's synthesis of calothrixin B.](marinedrugs-14-00017-g005){#marinedrugs-14-00017-f005}

### 2.2.3. Nagarajan's Synthesis {#sec2dot2dot3-marinedrugs-14-00017}

Nagarajan *et al.* \[[@B40-marinedrugs-14-00017]\] outlined a strategy for the synthesis of calothrixin B featuring a directed *o*-metalation reaction as a key step, as outlined in [Scheme 4](#marinedrugs-14-00017-f006){ref-type="scheme"}. The synthesis began with the coupling of the commercially available reagents, ethyl indole-2-carboxylate (**20**) and quinoline-3-carboxaldehyde (**26**) in the presence of TMG in MeOH followed by the oxidation of the intermediate product with Dess-Martin periodinane (DMP) in CH~2~Cl~2~/AcOH. This two-step process yielded compound **27**, which was then cyclized by an intramolecular directed *o*-lithiation reaction using lithium tetramethylpiperidide (LiTMP) to form calothrixin B in 48% yield. This synthetic methodology offers a three-step route to calothrixin B from commercially available reagents in an overall yield of 38%.

![Nagarajan's synthesis of calothrixin B.](marinedrugs-14-00017-g006){#marinedrugs-14-00017-f006}

### 2.2.4. Mal's Synthesis {#sec2dot2dot4-marinedrugs-14-00017}

Mal *et al.* \[[@B41-marinedrugs-14-00017]\] reported a two-step synthesis of calothrixin B from the *N*-protected indololactone (**28**) as outlined in [Scheme 5](#marinedrugs-14-00017-f007){ref-type="scheme"}. This reagent was prepared in three simple steps from commercially available α-acetobutyrolactone \[[@B51-marinedrugs-14-00017]\]. Treatment of compound **28** with 4-bromoquinoline (**29**) in the presence of lithium diisopropylamide (LDA) in tetrahydrofuran (THF) at −78 °C afforded an inseparable mixture of compounds **30a** and **30b**. However, after the removal of methoxymethylene (MOM) group using HCl, it gave a mixture of calothrixin B (**1b**) and its regioisomer (**31b**) that could be easily separated in the ratio of 40% and 6%, respectively. This synthetic methodology afforded calothrixin B with an overall yield of 47% for two steps starting from compound **28**.

![Mal's synthesis of calothrixin B and its regioisomer.](marinedrugs-14-00017-g007){#marinedrugs-14-00017-f007}

2.3. Ring D Closure as the Last Step in the Construction of the Indolo\[3,2-j\]Phenanthridine Framework {#sec2dot3-marinedrugs-14-00017}
-------------------------------------------------------------------------------------------------------

Another strategy for the calothrixin synthesis involves cyclizing ring D as the last step in the construction of calothrixin scaffold. A number of contributions have been made to this category of syntheses. These include four independent publications by Kusurkar *et al.* in 2012 \[[@B42-marinedrugs-14-00017]\], Nagarajan *et al.* in 2013 \[[@B43-marinedrugs-14-00017]\], Mohanakrishnan *et al.* in 2014 \[[@B44-marinedrugs-14-00017]\], Kumar *et al.* in 2014 \[[@B45-marinedrugs-14-00017]\], and Hibino *et al.* in 2012 \[[@B46-marinedrugs-14-00017]\].

### 2.3.1. Kusurkar's Synthesis {#sec2dot3dot1-marinedrugs-14-00017}

Kusurkar *et al.* \[[@B42-marinedrugs-14-00017]\] have published a synthesis of calothrixins starting from 4-hydroxy carbazole as outlined in [Scheme 6](#marinedrugs-14-00017-f008){ref-type="scheme"}. The novelty of their synthetic route is the unprecedented use of DMF-NaOMe as a reagent for the reduction of the aldehyde group and the use of a high-yielding Pd-catalyzed coupling reaction to construct the ring D of the pentacyclic system. For example, the treatment of compound **35** with NaOMe in dry dimethyl formamide (DMF) and CuI at 120 °C resulted in the substitution of both bromine and benzyloxy groups with methoxy groups with concomitant reduction of the aldehyde resulting in the formation of the compound **36**. Pd-catalyzed cyclization of ring D of the scaffold to form compound **39** is another novel key step in this synthesis. The overall yield for Kusurkar's synthesis of calothrixin B was 25% for nine steps.

![Kusurkar's total synthesis of calothrixin B.](marinedrugs-14-00017-g008){#marinedrugs-14-00017-f008}

### 2.3.2. Nagarajan's Synthesis {#sec2dot3dot2-marinedrugs-14-00017}

In addition to developing a synthetic route for calothrixins that involved the closure of ring C in the last step, Nagarajan *et al.* \[[@B43-marinedrugs-14-00017]\] has also accomplished a synthesis in which ring D was closed last in the preparation of the five-membered ring system, followed by the installation of the necessary substitutions to produce calothrixin B as shown in [Scheme 7](#marinedrugs-14-00017-f009){ref-type="scheme"}. This synthesis featured a prominent Pd-catalyzed intramolecular cross-coupling reaction via C-H activation using an appropriately substituted carbazole derivative to construct the indolophenanthridine core ring system of calothrixins. This is the first reported synthesis of calothrixin pentacycles without any protection on the indole N atom. The overall yield for calothrixin B in this Nagarajan's synthesis is 35% for five steps starting from 4-methoxycarbazole.

![Nagarajan's synthesis of calothrixins A and B.](marinedrugs-14-00017-g009){#marinedrugs-14-00017-f009}

### 2.3.3. Mohanakrishnan's Synthesis {#sec2dot3dot3-marinedrugs-14-00017}

Mohanakrishnan *et al.* have reported a linear synthesis of calothrixin B using the thermal electro cyclization of 2-nitroarylvinyl-3-phenylsulfonylvinylindole as the key step as outlined in [Scheme 8](#marinedrugs-14-00017-f010){ref-type="scheme"} \[[@B44-marinedrugs-14-00017]\]. In this key step, the 2,3-divinylidole intermediate generated from compound **52** by treatment with Me~2~SO~4~ was subjected to thermal cyclization in refluxing xylenes to afford the carbazole derivative **53**. Mohanakrishnan's total synthesis thus afforded calothrixin B from 2-methylindole in 14 steps with an overall yield of about 8%.

![Mohanakrishnan's synthesis of calothrixins A and B.](marinedrugs-14-00017-g010){#marinedrugs-14-00017-f010}

### 2.3.4. Kumar's Synthesis {#sec2dot3dot4-marinedrugs-14-00017}

Kumar *et al.* \[[@B45-marinedrugs-14-00017]\] reported the total synthesis of calothrixin B via multiple palladium-mediated C-X/C-H cross intramolecular coupling reactions as outlined in [Scheme 9](#marinedrugs-14-00017-f011){ref-type="scheme"}. The salient feature of this synthesis is the two intramolecular C-X/C-H cross coupling reactions of the intermediates **60** to form compound **61** and **63** to form the compound **64**. The intermediate **60** was cyclized under intramolecular cross coupling reaction condition using Pd(OAc)~2~, PCy~3~, and JohnPhos to afford the carbazole derivative **61**. The cyclization of **63** was carried out using Pd(OAc)~2~, PCy~3~, and K~2~CO~3~ to afford the compound **64.** Kumar's methodology thus accomplished the synthesis of calothrixin B in 7 steps starting from 2,5-dimethoxybenzaldehyde in an overall yield of 50%.

![Kumar's synthesis of calothrixins B.](marinedrugs-14-00017-g011){#marinedrugs-14-00017-f011}

Compound **60** in Kumar's synthesis has also been converted to the key intermediate **64** in three steps as shown in [Scheme 10](#marinedrugs-14-00017-f012){ref-type="scheme"}. In this synthesis, rings B and D of the calothrixin scaffold were cyclized in one step by intramolecular C-X/C-H cross coupling reaction using Pd(OAc)~2~, PCy~3~, and JohnPhos in the presence of K~2~CO~3~ in DMF to afford the key intermediate **64**.

![Alternate synthesis of compound **64**.](marinedrugs-14-00017-g012){#marinedrugs-14-00017-f012}

### 2.3.5. Hibino's Synthesis {#sec2dot3dot5-marinedrugs-14-00017}

Hibino *et al.* \[[@B46-marinedrugs-14-00017]\] synthesized calothrixin B and other *N*-alkyl-calothrixins using a biomimetic approach featuring a key allene-mediated electrocyclic reaction of the 6π-electron system, as outlined in [Scheme 11](#marinedrugs-14-00017-f013){ref-type="scheme"}. The synthesis of the key intermediate, indolo\[2,3-*a*\]carbazole (**72**), was carried out by an allene-mediated electrocyclic reaction of MOM-protected compound **71** in the presence of tBuOK in tBuOH-THF. This electrocyclization involved the two \[*b*\]-bonds of indole units and the allene double bond generated *in situ*. The overall yield for Hibino's synthesis of calothrixin B from 2-bromoindole-3-carboxaldehyde is 22% for nine steps.

![Hibino's synthesis of calothrixin B.](marinedrugs-14-00017-g013){#marinedrugs-14-00017-f013}

2.4. Simultaneous Closure of Rings C and D {#sec2dot4-marinedrugs-14-00017}
------------------------------------------

Only one methodology of calothrixin synthesis has been developed in which multiple rings were cyclized in a one-pot synthesis. This report was published by Mohanakrisnan *et al.* \[[@B47-marinedrugs-14-00017]\] in 2013, prior to their report in 2014 \[[@B44-marinedrugs-14-00017]\] in which ring D was the last ring closure step.

### Mohanakrishnan's Synthesis

Mohanakrishnan *et al.* \[[@B47-marinedrugs-14-00017]\] reported another novel synthesis of calothrixin B involving a key FeCl~3~ mediated domino reaction of an enamine derivative, as outlined in [Scheme 12](#marinedrugs-14-00017-f014){ref-type="scheme"}. In this key step, FeCl~3~ was used to cyclize the key intermediate **79** to afford calothrixin B. Both rings C and D were created in a sigle step in this synthesis. The overall yield of calothrixin B from the compound **75** is 45% for six steps.

![Mohanakrishnan's synthesis of calothrixins B.](marinedrugs-14-00017-g014){#marinedrugs-14-00017-f014}

3. Bioactivities of Calothrixins {#sec3-marinedrugs-14-00017}
================================

The most therapeutically relevant biological activity reported for marine cyanobacterial metabolites is their cytotoxicity. While some antimicrobial studies were also conducted, calothrixins were majorly pursued to serve as novel anticancer molecules. Herein, we summarize all bioactivities conducted on calothrixins and their analogs. Following their isolation, calothrixins quickly gained recognition due to their anticancer activity as preliminary studies revealed a high potency against the human cervical cancer cell line, HeLa cells. Since then, calothrixins have been evaluated against several different cell lines and have been studied for their mode of action. Calothrixins were also evaluated for their antiparasitic activity. A summary of their bioactivities is found below.

3.1. Antiparasitic Activity {#sec3dot1-marinedrugs-14-00017}
---------------------------

Along with their discovery in 1999, Smith *et al.* \[[@B34-marinedrugs-14-00017]\] also reported that the cell extracts from cyanobacteria *Calothrix* were found to inhibit the growth of malarial strains. The two calothrixins, calothrixin A and B, were evaluated against the chloroquine (QC)-resistant malarial strain, *P. falciparum* FCR-3 strain (QC-sensitive), and were found to be effective in a dose-dependent manner. The IC~50~ values were observed to be 58 nM and 180 nM, respectively, compared with 83 nM IC~50~ value for chloroquine in the same assay \[[@B34-marinedrugs-14-00017]\].

In an attempt to find a better lead against malaria, Hibino *et al.* \[[@B46-marinedrugs-14-00017]\] synthesized and evaluated several *N*-alkyl calothrixin analogs for their activity against the chloroquine-resistant strain ([Table 2](#marinedrugs-14-00017-t002){ref-type="table"}). The results for antimalarial activity were compared against chloroquine. Calothrixin B was observed to be the most active (IC~50~ = 120 nM), concurring with the findings of Rickards *et al.* \[[@B34-marinedrugs-14-00017]\]. Calothrixin A was found to be almost equally active (IC~50~ = 185 nM ) as calothrixin B. Although all compounds showed antimalarial activity, substitution of the indole nitrogen atom with various alkyl groups led to a decrease in activity. Among the analogs, 2-hydroxyethyl group showed slightly better activity in comparison to the other alkyl substitutions.

In addition to its antimalarial activities, Smith *et al.* \[[@B52-marinedrugs-14-00017],[@B53-marinedrugs-14-00017]\] reported the antibacterial activity of calothrixin A against *Bacillus subtilis* 168, where it was found to be inhibiting the bacterial growth in a dose-dependent manner without any cell lysis. A complete growth inhibition was achieved at 16 µM concentration.

marinedrugs-14-00017-t002_Table 2

###### 

Antimalarial activity calothrixin analogs against FCR-3 strain.

  Compound                             IC~50~ against FCR-3 Strain (nM)   Compound                             IC~50~ against FCR-3 Strain (nM)
  ------------------------------------ ---------------------------------- ------------------------------------ ----------------------------------
  ![](marinedrugs-14-00017-i001.jpg)   185                                ![](marinedrugs-14-00017-i002.jpg)   120
  ![](marinedrugs-14-00017-i003.jpg)   380                                ![](marinedrugs-14-00017-i004.jpg)   490
  ![](marinedrugs-14-00017-i005.jpg)   380                                ![](marinedrugs-14-00017-i006.jpg)   220
  ![](marinedrugs-14-00017-i007.jpg)   320                                ![](marinedrugs-14-00017-i008.jpg)   640
  ![](marinedrugs-14-00017-i009.jpg)   250                                ![](marinedrugs-14-00017-i010.jpg)   330
  ![](marinedrugs-14-00017-i011.jpg)   180                                                                     

3.2. Anticancer Activity {#sec3dot2-marinedrugs-14-00017}
------------------------

Along with their antimalarial activity, Rickards *et al.* \[[@B34-marinedrugs-14-00017]\] reported calothrixins to be potent against HeLa cells. The corresponding IC~50~ values for calothrixin A and B against the human cervical cancer cell line, HeLa cells, were observed to be 40 nM and 350 nM, respectively. Calothrixins showing similar inhibitory effects against cancer cell lines and malarial strains indicated that they may share a common mode of action. Following this report, in 2003, Waring *et al.* \[[@B54-marinedrugs-14-00017]\] studied the effect of calothrixin A on apoptosis in human Jurkat cancer cells. A well-known inducer of apoptosis, menadione, was used as a positive control to compare the effects of calothrixin A \[[@B55-marinedrugs-14-00017]\]. Calothrixin A was observed to induce cell death via apoptosis in a time- and concentration-dependent manner, and was found to be more potent than menadione in anti-proliferative activity, with IC~50~ values of 1.6 µM and 4.7 µM, respectively ([Table 3](#marinedrugs-14-00017-t003){ref-type="table"}). IC~50~ values for calothrixin A- and menadione-induced apoptosis were 0.6 µM and 12 µM respectively. Both calothrixin A and menadione were observed to induce cell cycle arrest in the G~2~/M phase, but the concentration required for calothrixin A was much lower than for menadione. The cell cycle arrest in the G~2~/M phase indicated intracellular DNA damage, which was further supported by direct DNA damage observed in cell-free experiments.

Both calothrixin A and menadione were found to be redox active through the observation of additional oxygen intake when added to reductant dithiothreitol (DTT, 2 mM at pH 8.0). Quinones can redox cycle by one or two electron transfers, generating reactive oxygen species (ROS), by which they can damage DNA and induce apoptosis \[[@B56-marinedrugs-14-00017]\]. It was postulated that the ring structure of calothrixin might act as a DNA intercalator that might be responsible for its anticancer activity. In addition, calothrixin A was observed to be cleaving DNA, though less effectively than menadione. Menadione caused significant DNA damage at 10 µM after 60 min incubation, whereas calothrixin A exhibited the same effect at 500 µM.
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###### 

Cell cytotoxicities and apoptotic activities of calothrixin A and menadione.

  Compound        Structure                            IC~50~ for Cytotoxicity   IC~50~ for Apoptosis
  --------------- ------------------------------------ ------------------------- ----------------------
  Calothrixin A   ![](marinedrugs-14-00017-i012.jpg)   1.6 µM                    0.6 µM
  Menadione       ![](marinedrugs-14-00017-i013.jpg)   4.7 µM                    12 µM

One of the known modes of action for anticancer activities of quinones is by the generation of ROS through redox cycling \[[@B56-marinedrugs-14-00017]\]. In 2004, Wilkes *et al.* \[[@B57-marinedrugs-14-00017]\] carried out a comparative study of bioactivities of calothrixins and some structurally related quinones. This was the first structure--activity relationship study done for calothrixins. The cytotoxic effect of various quinones was evaluated against human cervical cancer cells, HeLa cells, using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay ([Table 4](#marinedrugs-14-00017-t004){ref-type="table"}). Calothrixin A and calothrixin B showed cytotoxicity against HeLa cells with EC~50~ values of 0.12 µM and 0.24 µM, respectively. Calothrixin B and ellipticine quinone, which differ by the ring E, showed comparable activities, indicating that there might be only a limited role for the ring E in dictating the bioactivity of calothrixins. Introducing the MOM group on the indole nitrogen seemed to decrease the potency of both calothrixin B and ellipticine quinone with EC~50~ values of 0.42 µM and 0.37 µM, respectively. Further, replacement of the heteroaromatic ring-D with a carbocyclic aromatic ring in ellipticine and its *N*-methoxymethyl analog also led to a decrease in potency, benzocarbazoledione (0.43 µM), and *N*-MOM-benzocarbazoledione (1.6 µM). Menadione showed activity at 3.7 µM. Absence of activity for uncyclized precursors of benzocarbazoledione and *N*-MOM-benzocarbazoledione indicated the importance of a tetracyclic quinone ring structure. In case of all the quinones with EC~50~ \< 1.6 µM, the quinones were observed to be reduced to their respective semiquinones, though no direct correlation was observed between the reduction potentials and bioactivity.
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###### 

Cytotoxicity of quinones against HeLa cells.

  Compound                                              Structure                            EC~50~ (µM) HeLa Cells
  ----------------------------------------------------- ------------------------------------ ------------------------
  Calothrixin A                                         ![](marinedrugs-14-00017-i014.jpg)   0.12 ± 0.01
  Calothrixin B                                         ![](marinedrugs-14-00017-i015.jpg)   0.24 ± 0.04
  *N*-MOM-calothrixin B                                 ![](marinedrugs-14-00017-i016.jpg)   0.42 ± 0.02
  Ellipticine quinone                                   ![](marinedrugs-14-00017-i017.jpg)   0.15 ± 0.09
  *N*-MOM-ellipticine quinone                           ![](marinedrugs-14-00017-i018.jpg)   0.37 ± 0.08
  Benzocarbazoledione                                   ![](marinedrugs-14-00017-i019.jpg)   0.43 ± 0.01
  *N*-MOM-Benzocarbazoledione                           ![](marinedrugs-14-00017-i020.jpg)   1.6 ± 1.0
  Menadione                                             ![](marinedrugs-14-00017-i021.jpg)   3.7 ± 0.3
  Uncyclized precursor to benzocarbazoledione           ![](marinedrugs-14-00017-i022.jpg)   \>50
  Uncyclized precursor to *N*-MOM-benzocarbazoledione   ![](marinedrugs-14-00017-i023.jpg)   \>50

To study the involvement of the ring structure and the mechanism of action in the inhibitory effects, the same group \[[@B58-marinedrugs-14-00017]\] synthesized and analyzed the activity of various simple quinone analogs of calothrixin B ([Table 5](#marinedrugs-14-00017-t005){ref-type="table"}) in 2007. The compounds were evaluated for their selectivity and antiproliferative activity, using an MTT assay, against three different cell lines: human cervical cancer (HeLa) cells, murine P388 macrophage cancer cells, and simian non-cancerous CV-1 cells.

In this study, calothrixin B was found to be the most potent against HeLa cells (0.25 µM) followed by indolophenanthrene-7,13-dione analog (1.5 µM), indicating the importance of nitrogen in ring D. The activity was further decreased with the deletion of ring E of this analog to form benzoncarbzoledione (1.8 µM). The rest of the analogs showed moderate activity ranging from 7 to 13 µM, while the carbazole-1,4-dione analog was found to be inactive. The results were not as consistent for the P388 cell line, where murrayaquinone (2.3 µM) and 2-methylcarbazoledione (1 µM) were found to be more active compared to calothrixin B (9 µM) or other analogs, whereas calothrixin B and 2-methylcarbazoledione showed similar activity with 2.4 µM and 1.7 µM, respectively, against non-cancerous cell line CV-1. The rest of the analogs had either very low activity or no measurable activity. These studies indicated the importance of rings A--D in the activity of calothrixins. Also, a selective usage of calothrixin B against human cervical cancer cells was indicated by the 10-fold higher effectiveness against HeLa cells (0.25 µM) as compared to CV-1 (2.4 µM) and 38 times more compared to P388 (9 µM). The quinones containing tetra- and penta cyclic systems (calothrixin-B, indolophenanthrene-7,13-dione and benzocarbazole-1,4-dione) were found to be more active against HeLa cells as compared to p388 and CV-1 cells. However, the trend was reversed in the quinones containing bi- and tricylic systems (murrayaquinone, 2-methylcarbazoledione, and isoquinoline-5,8-dione).

In 2009, another group, Hecht *et al.* \[[@B59-marinedrugs-14-00017]\], published a study to determine the mechanism of action and the stage of the cell cycle that is targeted by the calothrixins. Calothrixin A and B and the *N*-methylated derivative were synthesized and tested against CEM leukemia cells to measure their cytotoxicity using an MTT assay. The activity of calothrixin analogs were compared to camptothecin, which is known to cause irreversible DNA damage during the S phase. Delay in S phase due to DNA damage is associated with a block in replication. The IC~50~ value for calothrixin A was found to be five-fold higher than campothecin and the other two analogs were observed to be much less potent, with *N*-methylcalothrixin B being the least at 5 µM compared to calothrixin B at 1 µM ([Table 6](#marinedrugs-14-00017-t006){ref-type="table"}).
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###### 

Antiproliferative activity of calothrixin B and analogs in MTT assay against HeLa cells, P388 cells, and CV-1 cells.

  Compound                        Structure                            EC~50~ (µM) HeLa Cells   EC~50~ (µM) P388 Cells   EC~50~ (µM) CV-1 Cells
  ------------------------------- ------------------------------------ ------------------------ ------------------------ ------------------------
  Calothrixin B                   ![](marinedrugs-14-00017-i024.jpg)   0.25 ± 0.05              9 ± 2                    2.4 ± 0.7
  Indolophenanthrene-7,13-dione   ![](marinedrugs-14-00017-i025.jpg)   1.5 ± 0.3                \>50                     \>50
  Benzocarbzoledione              ![](marinedrugs-14-00017-i026.jpg)   1.8 ± 0.1                \>50                     \>50
  Carbazole-1,4-dione             ![](marinedrugs-14-00017-i027.jpg)   \>50                     \>50                     \>50
  Murrayaquinone                  ![](marinedrugs-14-00017-i028.jpg)   13 ± 1                   2.3 ± 0.3                10 ± 2
  2-Methylcarbazoledione          ![](marinedrugs-14-00017-i029.jpg)   7 ± 1                    1.0 ± 0.1                1.7 ± 0.4
  Isoquinoline-5,8-dione          ![](marinedrugs-14-00017-i030.jpg)   12 ± 1                   9 ± 2                    \>50

The effect on the cell cycle was studied for these compounds using a mitotic inhibitor nocodazole, which blocks re-entry of cells into the G~1~ phase. Calothrixin B was observed to arrest the G~1~ phase at 0.1 μM concentrations, whereas calothrixin A and *N*-methylcalothrixn B showed no effects at the same concentration. At higher concentrations, calothrixin A and *N*-methylcalothrixn B led to cell accumulation in S and G~2~/M phase. Compared to camptothecin, these effects were found to be readily reversible. Calothrixins were also evaluated for their activity against topoisomerase I. The effects of calothrixins were studied keeping camptothecin as a positive control, which is a known topoisomerase I poison \[[@B60-marinedrugs-14-00017]\]. It was observed that calothrixins A, B, and *N*-methylcalothrixin B were capable of stabilizing the covalent topoisomerase I/DNA complex at 18%, 13%, and 11%, respectively, compared to 100% at 5 µM concentration of camptothecin.

Calothrixins and their analogs were observed to be affecting different stages of cell cycle in a reversible manner, leading to low micromolar range cytotoxicities. Thus, calothrixins have shown a wide array of activity including antimalarial, anticancer, and antibacterial. The modes of action of calothrixins' bioactivities have not been fully deciphered yet.
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###### 

Cytotoxicity effects against CEM leukemia cell line and topoisomerase I inhibition.

  Compound                 Structure                            IC~50~ (µM) in CEM Leukemia Cells   \% Topo I DNA Cleavage at 5 µM   \% NaCl Induced Reversibility at 5 µM
  ------------------------ ------------------------------------ ----------------------------------- -------------------------------- ---------------------------------------
  Camptothecin             ![](marinedrugs-14-00017-i031.jpg)   0.04 ± 0.01                         100                              100
  Calothrixin A            ![](marinedrugs-14-00017-i032.jpg)   0.20 ± 0.02                         18                               17
  Calothrixin B            ![](marinedrugs-14-00017-i033.jpg)   1.05 ± 0.30                         13                               16
  *N*-methycalothrixin B   ![](marinedrugs-14-00017-i034.jpg)   5.13 ± 0.72                         11                               13

4. Conclusions {#sec4-marinedrugs-14-00017}
==============

While the medicinal and biosynthetic potential of terrestrial plants and microbes is fairly well studied, comparatively little is known regarding the chemistry and biological activity of organisms in the marine environment. A unique group of oxygenic photosynthetic bacteria known as cyanobacteria populate diverse habitats throughout the world. Their potential as a good source of new therapeutic lead compounds has been realized during the last few decades. Calothrixins, which are cyanobacterial metabolites, have demonstrated a diverse range of bioactivities that include antimalarial, anticancer, and antibacterial properties. They have been observed to target various aspects of RNA synthesis in bacteria. Further investigation of the exact mechanism for their bioactivity is still required for many analogs, which will be beneficial for the ongoing development and lead optimization. Several research groups have developed synthetic routes to obtain these natural products. This review emphasized the synthetic progress accomplished within the past six years in developing new synthetic routes. Since 2009, 11 novel syntheses have been published to improve upon the efficiency in the production of calothrixins. The number of steps in the various synthetic strategies ranges from 2 to 14, while the overall yield to construct calothrixin B ranges from 8% to 50%. Thus, significant progress has been made in the last decade in attaining more efficient synthesis of calothrixins, which may aid to establish calothrixins as a potential anti-cancer candidate in the future.
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AcCl

:   Acetyl chloride

Ac~2~O

:   Acetic anhydride

AcOEt

:   Ethyl acetate

AcOH

:   Acetic acid

AIBN

:   Azobisisobutyronitrile

AlCl~3~

:   Aluminum chloride

BEt~3~

:   Triethylborane or triethylboron

BF~3~.OEt~2~

:   Boron trifluoride diethyl etherate

CAN

:   Ceric ammonium nitrate

CCl~4~

:   Carbon tetrachloride

CH~2~Cl~2~

:   Dichloromethane

CH~3~CN

:   Acetonitrile

COSY

:   Correlation spectroscopy

c-PC

:   c-Phycocyanin

CSA

:   Camphorsulfonic acid

CuI

:   Copper(I) iodide

(CuOTf)~2~.toluene

:   Trifluoromethanesulfonate toluene complex

DMAP

:   4-Dimethylaminopyridine

DMF

:   Dimethylformamide

DMP

:   Dess-Martin periodinane

DMSO

:   Dimethyl sulfoxide

DoM

:   Directed *o*-metalation

DTT

:   Dithiothreitol

Et~2~NH

:   Diethylamine

Et~3~SiH

:   Triethylsilane

FeCl~3~

:   Iron(III) chloride

HCO~2~H

:   Formic acid

HDACs

:   Histone deacetylases

HIV

:   Human immunodeficiency virus

H~2~O~2~

:   Hydrogen peroxide

K~2~CO~3~

:   Potassium carbonate

LDA

:   Lithium diisopropylamide

LiTMP

:   Lithium tetramethylpiperidide

LTA

:   Lead tetracetate

MeOH

:   Methanol

Mn(OAc)~3~

:   Manganese triacetate

MOM

:   Methoxymethyl protecting group

MTT

:   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NaCNBH~3~

:   Sodium cyanoborohydride

NaH

:   Sodium hydride

NaOH

:   Sodium hydroxide

NaOMe

:   Sodium methoxide

NBS

:   *N*-bromosuccinimide

*n*-BuLi

:   *n*-Butyllithium

NH~2~NH~2~.H~2~O

:   Hydrazine hydrate solution

Pb(OAc)~4~

:   Lead(IV) acetate

PCC

:   Pyridinium chlorochromate

Pd/C

:   Palladium on carbon

PdCl~2~(PPh~3~)~2~

:   Bis(triphenylphosphine)palladium(II) dichloride

Pd~2~(dba)~3~

:   Tris(dibenzylideneacetone)dipalladium(0)

Pd(dppf)Cl~2~

:   \[1,1′-Bis(diphenylphosphino)ferrocene\] dichloropalladium(II)

Pd(OAc)~2~

:   Palladium acetate

Pd(TFA)~2~

:   palladium(II) trifluoroacetate

PhCN

:   Benzonitrile

(PhSe)~2~

:   Diphenyl diselenide

PMB

:   *p*-Methoxybenzyl

PMBCl

:   *p*-Methoxybenzyl chloride

P(*o*-tol)~3~

:   Tri(*o*-tolyl)phosphine

POCl~3~

:   Phosphoryl chloride

PPh~3~

:   Triphenylphosphine

*p*-TSA

:   *p*-Toluenesulfonic acid

PTT

:   Polytrimethylene terephthalate

rac-BINAP

:   Racemic 2,2′-bis(diphenylphosphino)-1,1′-binaphthalene

ROS

:   Reactive oxygen species

TBAD

:   Bis(tetrabutylammonium) dichromate

TBHP

:   *Tert*-butyl hydroperoxide

Tf~2~O

:   Trifluoromethanesulfonic anhydride

THF

:   Tetrahydrofuran

THP

:   Tetrahydropyran

TMG

:   1,1,3,3-Tetramethylguanidine

TMP

:   2,2,6,6-Tetramethylpiperidine

TMSI

:   Trimethylsilyl iodide
